What Cannabis Does to Heart Rate and Blood Pressure, and Which Patients Should Take That Seriously

Smoking cannabis produces a dose-dependent rise in heart rate, elevated blood pressure while lying down, and a fall in blood pressure on standing. Those are the hemodynamic effects described in the cardiology literature, not side effects that occur occasionally.

A 2025 systematic review and meta-analysis in Heart pooled 24 pharmacoepidemiological studies and reported elevated risk estimates for acute coronary syndrome, stroke, and cardiovascular death among people who use cannabis.

Most patients discussing cannabis with a physician are discussing pain, sleep, or anxiety. Very few raise the circulatory system, and very few clinicians ask. That omission matters most in exactly the population where it is easiest to miss: an adult with coronary disease, hypertension, or an arrhythmia who is quietly using cannabis for something else entirely.

The acute effects are predictable enough to plan around, and the risk literature is consistent enough in direction that a cardiac history should change how a cannabis conversation goes. Those are two different arguments and both are worth making.

The acute hemodynamic profile of smoked cannabis has been described in the cardiology literature for decades. Writing in Circulation, Murray Mittleman and colleagues summarized it as a dose-dependent increase in heart rate, supine hypertension, and postural hypotension. In plain terms: the heart speeds up, blood pressure rises while the person is lying down, and blood pressure falls when they stand.

Mechanistically this is CB1 receptor activity interacting with autonomic control of the cardiovascular system. The tachycardia is the most reliable and most easily measured effect, and it is the one a patient is most likely to notice and describe as their heart pounding. The postural drop is the one that produces the lightheadedness on standing that new users frequently report and that can produce a fall in an older patient.

The American Heart Association addressed this directly in a 2020 scientific statement in Circulation, which reviewed medical and recreational cannabis from a cardiovascular perspective and concluded that while cannabis may have therapeutic benefits, few of them are cardiovascular in nature, and that many of the concerning health implications are.

CBD is often presented as the component with no cardiovascular activity. A randomized, placebo-controlled crossover study published in JCI Insight tested that assumption. Nine healthy male volunteers received a single 600 mg dose of cannabidiol or placebo with continuous cardiovascular monitoring.

CBD reduced resting systolic blood pressure by about 6 mmHg and stroke volume by about 8 mL, with a compensatory increase in heart rate and maintained cardiac output. Before and after a stress task, systolic pressure was about 5 mmHg lower and heart rate about 10 beats per minute higher on CBD. In response to a cold stress challenge, the blood pressure rise was blunted by about 6 mmHg with a 7 beat per minute heart rate increase and lower total peripheral resistance.

This is a nine-person single-dose study in healthy young men, which limits how far it generalizes. It does establish that CBD has measurable hemodynamic activity, which matters for a patient already taking antihypertensive medication and for anyone who assumes the non-intoxicating cannabinoid carries no circulatory effect at all.

The best-known study of acute cardiac risk is the Determinants of Myocardial Infarction Onset Study, reported by Mittleman and colleagues in Circulation. Investigators interviewed 3,882 patients an average of four days after an acute myocardial infarction and used a case-crossover design, which compares each patient’s exposure in the hour before symptoms began against their own usual frequency of that exposure.

Of those 3,882 patients, 124 reported smoking cannabis in the prior year, 37 within 24 hours, and 9 within one hour of symptom onset. The risk of infarction onset was elevated 4.8 times over baseline in the 60 minutes after cannabis use, with a 95 percent confidence interval from 2.4 to 9.5, and the elevation fell off rapidly after that window.

Two things are true at once here. The relative risk in that hour is substantial, and the absolute event is rare, which is how the authors themselves framed it. For a healthy 25-year-old the absolute risk remains very small. For someone with established coronary disease, a transient fivefold multiplier on an already elevated baseline is a different calculation entirely.

A 2024 analysis in the Journal of the American Heart Association used Behavioral Risk Factor Surveillance System data from 27 states and two territories, covering 434,104 respondents aged 18 to 74. Daily cannabis use was reported by 4 percent and non-daily use by 7.1 percent. After adjustment for tobacco use and other characteristics, daily cannabis use was associated with myocardial infarction at an adjusted odds ratio of 1.25, stroke at 1.42, and a composite of coronary heart disease, myocardial infarction, and stroke at 1.28, with lower odds at intermediate frequencies of use.

The result that resists the easiest objection is the never-tobacco-smoker analysis. Among respondents who had never smoked tobacco, daily cannabis use was associated with myocardial infarction at an odds ratio of 1.49, stroke at 2.16, and the composite at 1.77. Relationships were similar in men under 55 and women under 65, the groups at risk of premature cardiovascular disease.

A systematic review and meta-analysis published in Heart in 2025 pooled 24 pharmacoepidemiological studies. The estimated risk ratios were 1.29 for acute coronary syndrome, 1.20 for stroke, and 2.10 for cardiovascular death. A sensitivity analysis restricted to cohort studies gave a comparable result of 1.32. The authors concluded that these findings should encourage investigating cannabis use in every patient presenting with a serious cardiovascular disorder.

Not every analysis agrees, and the disagreements are worth stating rather than skipping. A separate meta-analysis of 17 observational studies covering 1,902,481 individuals found no statistically significant association between ever using cannabis and myocardial infarction alone, with a risk ratio of 1.25 and a confidence interval from 0.91 to 1.71, nor with stroke alone at 1.38 with an interval from 0.88 to 2.16. The composite of any adverse cardiovascular event was significant at 1.48.

A two-sample Mendelian randomization study, which uses genetic variants associated with cannabis use to reduce confounding, found no causal effect of genetically predicted cannabis use on coronary artery disease, myocardial infarction, stroke, atrial fibrillation, or heart failure. After adjusting for tobacco use and body mass index, a multivariable analysis did suggest an effect on small vessel stroke and on atrial fibrillation.

The honest reading is that the observational signal is consistent in direction and inconsistent in magnitude, that ever-use is a poor exposure measure while frequency of use behaves more like a dose, and that no design has cleanly separated cannabis from tobacco, from combustion, and from the health characteristics of people who use cannabis daily. That is a case for uncertainty about size, not for dismissal.

For a patient with no cardiac history and no risk factors, the acute effects are the practical issue: expect a faster heart rate, expect lightheadedness on standing, stand up slowly, and know that the effect is larger with inhaled routes because peak concentrations arrive faster.

For a patient with coronary disease, prior myocardial infarction, poorly controlled hypertension, an arrhythmia history, or prior stroke, cannabis belongs in the cardiology conversation rather than in a separate lane. That is true whether the product is medical or recreational and whether the reason for use is pain, sleep, or anything else. Combustion adds a well-established insult to the vasculature that has nothing to do with cannabinoids and is avoidable by changing route.

The clinical ask is modest and specific. Ask about cannabis by name during cardiac evaluation, record frequency rather than a yes or no, and treat daily use as the exposure category the risk data actually describe. Patients rarely volunteer it, and the evidence above is the reason that silence is a problem.

The acute hemodynamic evidence is strong and old. Heart rate response, supine pressure rise, and postural drop have been reproduced in controlled human administration studies for decades and are not in dispute.

The chronic risk evidence is observational and consistent in direction. Several independent designs, including a meta-analysis of pharmacoepidemiological studies and a large survey analysis restricted to people who never smoked tobacco, point the same way. Consistency across designs is meaningful even when each individual design has limits.

Most of the population evidence is cross-sectional and relies on self-reported cannabis use and self-reported cardiovascular events, which invites both misclassification and reverse causation. A person who had a heart attack may recall and report use differently than someone who did not.

Mendelian randomization, which is less vulnerable to confounding, did not support a causal effect on most cardiovascular outcomes, though it did suggest one for small vessel stroke and atrial fibrillation after adjustment. And a separate meta-analysis found ever-use not significantly associated with myocardial infarction or stroke individually. Magnitude remains genuinely uncertain.

None of this establishes that cannabis causes myocardial infarction or stroke in any individual patient, nor does it quantify absolute risk for a specific person. Relative risk estimates without an individual baseline are not a personal risk calculation.

The literature also does not separate route cleanly. Combustion carries its own vascular toxicity, and few studies have enough non-inhaled exposure to say whether oral or vaporized products carry the same signal.

Cardiovascular risk is the area where cannabis medicine most resembles early tobacco research: a consistent observational signal, a plausible acute mechanism, contested causal inference, and a long lag before the question is settled. The tobacco comparison is about the shape of the evidence, not the size of the effect, which appears considerably smaller here.

It is also the area where the gap between how patients think about cannabis and how cardiologists think about it is widest. A patient using an edible for arthritis pain does not file that under heart health. The evidence says it belongs there, at least for the conversation.

This is one of the few places in cannabis medicine where I will discourage a patient rather than help them optimize. If someone is a year out from a stent and using cannabis daily, the conversation is not about which product. It is about whether daily use is a good idea at all, and what the alternative plan for their symptom is.

The tachycardia gets dismissed too easily because it is transient and because experienced users stop noticing it. Partial tolerance to the cardiac response develops, but partial is the operative word, and a patient who no longer feels their heart racing has not stopped having the response.

The other thing I say often: route matters and it is the easiest variable to change. If a patient with vascular disease is going to use cannabis, smoking it is the version I have the least tolerance for, because combustion adds a harm that has nothing to do with the cannabinoid and is entirely avoidable.

Cannabis reliably raises heart rate, raises blood pressure while supine, and lowers it on standing. Multiple independent analyses associate cannabis use, and daily use in particular, with higher rates of acute coronary syndrome, stroke, and cardiovascular death, including among people who never smoked tobacco. The magnitude is uncertain. The direction is not. Anyone with cardiac disease or meaningful cardiovascular risk should discuss cannabis with their clinician before using it, and should treat frequency of use as the variable that matters most.

Read the frequency gradient rather than the yes-or-no comparison. The survey evidence found the strongest associations with daily use and proportionally lower odds at fewer days per month, which is the pattern you would expect if the exposure were doing something. Ever-use analyses, which lump a college experiment in with twenty years of daily smoking, are the ones that most often come back null.